Skip to main content

Invitrogen to Screen Drug Targets for Chroma Therapeutics

NEW YORK (GenomeWeb News) – Invitrogen said today it will continue to screen kinase inhibitors for Chroma Therapeutics after the companies extended an earlier agreement.
 
Invitrogen will use its SelectScreen service at its facility in Paisley, Scotland, to screen targets, study phylogenetic diversity, and explore signaling pathways to help Chroma Therapeutics “rapidly confirm the selectivity and potency of our small-molecule drugs,” Chroma Therapeutics CSO Alan Drummond said in a statement.
 
Drummond said Invitrogen’s kinases allow his company to determine if drug candidates are inhibiting the targeted kinases and how they interact with other kinases, and to predict potential side effects.
 
The agreement extends an earlier one between the companies that has been ongoing for over a year.
 
Financial terms of the agreement were not released.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.